wwwext.amgen.comOCT 12 min read$AMGN

Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz's Infringement Stands| Amgen

Amgen announced a U.S. appeals court upheld two Enbrel patents, affirming a 2019 ruling against Sandoz's biosimilar. The injunction prohibits Sandoz from selling its etanercept product. Amgen affiliates and Roche hold the patents.

Original reporting

wwwext.amgen.com

Published Oct 1, 2026, 12:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 1, 2026, 12:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz's Infringement Stands| Amgen — source image — Source · wwwext.amgen.com

Decision brief

The 30-second read

$AMGNBullishMed

Why it matters

The decision secures Amgen's exclusivity on a high-revenue biologic, likely supporting its stock and pressuring competitors.

Market read

Legal reinforcement of Amgen's patent portfolio may influence biotech valuations and competitive dynamics.

What to watch

Potential appeals or settlement negotiations could alter the immediate impact.

Relevance 1/10Novelty 7/10Timing: today

Background

Amgen announced a favorable appellate decision upholding two Enbrel patents, maintaining an injunction against Sandoz's biosimilar.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMGNBullishHigh confidence

Context

Court of Appeals upheld Amgen's Enbrel patents, confirming an injunction against Sandoz's biosimilar.

Expected impact

upward pressure as market prices in reinforced patent protection.

Evidence & confidence

Legal win removes competitive threat from Sandoz's biosimilar, improving Amgen's revenue outlook.

Market effects

Sector

Biotech sector may see heightened focus on patent litigation outcomes.

Regional

U.S. biotech stocks could benefit from reinforced IP enforcement.

Global

Limited to companies with competing biosimilars; broader market impact modest.

Counterpoint

What could challenge this read

Investors may question the long-term revenue boost if the biosimilar market remains limited.

Key entities

Company
Amgen
Biotech firm holding Enbrel patents.
Company
Sandoz
Novartis subsidiary producing Enbrel biosimilar.

Read at source ← All news

OCT 1

$AMGNMedAI 9/10

Imdelltra extends survival in relapsed small cell lung cancer, Korean investigator says

Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.

koreabiomed.com2 min

SEP 30

$AMGNMedAI 8/10

Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.

simplywall.st3 min

SEP 30

$AMGNMedAI 9/10

Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody

Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.

fiercebiotech.com2 min

SEP 29

$AMGNHighAI 9/10

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, meeting primary endpoints. Citi reaffirmed a Neutral rating and $405 price target, citing unanswered questions about efficacy and competitive profile. Amgen's Q2 2026 revenue grew 10% YoY to $10.1B, with key growth drivers like TEZSPIRE and UPLIZNA. However, legacy products faced biosimilar erosion, with Prolia and XGEVA sales declining 32% and 34%, respectively.

insidermonkey.com2 min

SEP 29

$AMGNLowAI 9/10

Amgen (AMGN), What Is Behind The Fresh Attention?

Amgen (AMGN) reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, boosting its autoimmune pipeline. Shares rose 15.5% in 90 days and 27.6% year-to-date. Analysts debate valuation, with some arguing it's 16.2% overvalued at $418.13, while others see potential in future cash flows. Legacy drug erosion and competitive pressures are key risks.

finance.yahoo.com3 min

SEP 27